|
| Trial | Study drug | Duration | Primary endpoints |
|
MTX-naїve | | | | |
abatacept* | AGREE [13] | ABT + MTX versus MTX | 12 months | DAS28-CRP < 2.6 at 12 months xRay progression at 12 months |
adalimumab | PREMIER [14] | ADA + MTX versus MTX versus ADA | 24 months | ACR50 at 12 months xRay progression at 12 months |
OPTIMA [15] | ADA + MTX versus PL + MTX | 6 months | DAS28-CRP < 3.2 at 78 wks no xRay progression at 78 wks |
certolizumab* | — | | | |
etanercept | ERA [16] | ETN versus MTX | 12 months | overall ACR response at 6 months xRay progression at 12 months |
COMET [17] | ETN + MTX versus MTX | 24 months | DAS28 < 2.6 at 12 months xRay progression at 12 months |
golimumab | GO-BEFORE [18] | GOL + MTX versus PL + GOL versus PL + MTX | 6 months | ACR50 at 6 months |
infliximab | ASPIRE [19] | IFL + MTX versus PL + MTX | 12 months | overall ACR response at 12 months xRay progression at 12 months |
rituximab** | IMAGE [20] | RTX + MTX versus MTX | 12 months | xRay progression at 12 months |
tocilizumab** | — | | | |
MTX/DMARD-IR | | | | |
abatacept | AIM [21] | ABT + MTX versus PL + MTX | 12 months | ACR20 at 6 months HAQ-DI at 12 months xRay progression at 12 months |
ATTEST [22] | ABT + MTX versus PL + MTX versus PL + INF | 12 months | DAS28 at 6 months |
adalimumab | ARMADA [23] | ADA + MTX versus PL + MTX | 6 months | ACR20 |
DE019 [24] | ADA + MTX versus PL + MTX | 12 months | ACR20 at 6 months HAQ-DI at 12 months xRay progression at 12 months |
certolizumab | RAPID-1 [25] | CER + MTX versus PL + MTX | 12 months | ACR20 at 6 months xRay progression at 12 months |
RAPID-2 [26] | CER + MTX versus PL + MTX | 6 months | ACR20 at 6 months |
FAST4WARD [27] | CER versus PL | 6 months | ACR20 at 6 months |
etanercept | Weinblatt [28] | ETN + MTX versus PL + MTX | 6 months | ACR20 at 6 months |
TEMPO [29] | ETN versus MTX versus ETN + MTX | 12 months | overall ACR response at 6 months xRay progression at 12 months |
ADORE [30] | ETN + MTX versus ETN | 4 months | improvement of > 1.2 units in DAS28 at 4 months |
golimumab | GO-FORWARD [31] | GOL + MTX versus PL + GOL versus PL + MTX | 6 months | ACR20 at 14 weeks HAQ-DI at 6 months |
infliximab | ATTRACT [32] | IFL + MTX versus PL + MTX | 30 weeks | ACR20 at 30 weeks |
rituximab*** | DANCER [33] | RTX + MTX versus PL + MTX | 6 months | ACR20 at 6 months |
SERENE [34] | RTX + MTX versus PL + MTX | 12 months | ACR20 at 6 months |
MIRROR [35] | RTX + MTX versus PL + MTX | 12 months | ACR20 at 12 months |
tocilizumab | OPTION [36] | TCZ + MTX versus PL + MTX | 6 months | ACR20 at 6 months |
LITHE [37] | TCZ + MTX versus PL + MTX | 24 months | HAQ-DI at 12 months xRay progression at 12 months |
TOWARD [38] | TCZ + DMARD versus PL + DMARD | 6 months | ACR20 at 6 months |
STREAM [39] | TCZ versus PL | 3 months | ACR20 at 3 months |
ROSE [40] | TCZ + DMARD versus PL + DMARD | 6 months | ACR20 at 6 months |
Anti-TNF IR | | | | |
abatacept | ATTAIN [41] | ABT + DMARD versus PL + DMARD | 6 months | ACR20 at 6 months HAQ-DI at 6 months |
adalimumab | — | | | |
certolizumab | — | | | |
etanercept | — | | | |
golimumab | GO-AFTER [42] | GOL + DMARDs versus PL + DMARDs | 6 months | ACR20 at 14 weeks |
infliximab | OPPOSITE [43] | IFL + MTX versus ETN + MTX | n.d. | none |
rituximab | REFLEX [44] | RTX + MTX versus PL + MTX | 24 months | ACR20 at 6 months |
tocilizumab | RADIATE [45] | TCZ + MTX versus PL + MTX | 6 months | ACR20 at 6 months |
|